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Abstract
Introduction: Lowering of hyperglycemia in the intensive care unit (ICU) is widely practiced. We investigated in
which way glucose regulation, defined as mean glucose concentration during admission, is associated with ICU
mortality in a medical and a surgical cohort.
Methods: Retrospective database cohort study including patients admitted between January 2004 and December
2007 in a 20-bed medical/surgical ICU in a teaching hospital. Hyperglycemia was treated using a computerized
algorithm targeting for glucose levels of 4.0-7.0 mmol/l. Five thousand eight hundred twenty-eight patients were
eligible for analyses, of whom 1,339 patients had a medical and 4,489 had a surgical admission diagnosis.
Results: The cohorts were subdivided in quintiles of increasing mean glucose. We examined the relation between
these mean glucose strata and mortality. In both cohorts we observed the highest mortality in the lowest and
highest strata. Logistic regression analysis adjusted for age, sex, Acute Physiology and Chronic Health Evaluation II
(APACHE II) score, admission duration and occurrence of severe hypoglycemia showed that in the medical cohort
mean glucose levels <6.7 mmol/l and >8.4 mmol/l and in the surgical cohort mean glucose levels < 7.0 mmol/l
and >9.4 mmol/l were associated with significantly increased ICU mortality (OR 2.4-3.0 and 4.9-6.2, respectively).
Limitations of the study were its retrospective design and possible incomplete correction for severity of disease.
Conclusions: Mean overall glucose during ICU admission is related to mortality by a U-shaped curve in medical
and surgical patients. In this cohort of patients a ‘safe range’ of mean glucose regulation might be defined
approximately between 7.0 and 9.0 mmol/l.
Introduction
Owing to inflammatory and neuro-endocrine derange-
ments in critically ill patients, stress hyperglycemia asso-
ciated with high hepatic glucose output and insulin
resistance is common in the intensive care unit (ICU)
[1]. This stress hyperglycemia is associated with poor
outcome [2]. Moreover, several studies report a deleter-
ious effect of glycemic variability over and above mean
glucose after correction for severity of disease [3-6].
In 2001, van den Berghe and colleagues [7] published
the first randomized controlled trial (RCT) comparing
normalization of glycemia by intensive insulin treatment
(IIT) with conventional glycemic control in a surgical ICU
(glucose target: 4.4 to 6.1 mmol/L versus 10.0 to
11.1 mmol/L). The authors reported an impressive reduc-
tion in mortality with IIT. The same group failed to repro-
duce these findings in the entire population of patients in
their medical ICU [8]; however, mortality was lower in the
predefined subgroup of patients receiving IIT for more
than 3 days. After the data were pooled from both RCTs,
IIT seemed to be associated with a reduction in mortality
[9]. On the basis of these ‘Leuven trials’,m a n yh o s p i t a l s
decided to implement protocols and target normalization
of glucose levels to improve patient care.
Recently, after the publication of two inconclusive
multicenter studies (the Volume Substitution and
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GluControl [11,12] studies) followed by the NICE-
SUGAR (Normoglycaemia in Intensive Care Evaluation-
Survival Using Glucose Algorithm Regulation) trial [13],
doubt was cast upon the benefits of tight glycemic con-
trol; the NICE-SUGAR trial investigators reported an
absolute increase in deaths at 90 days with IIT (glucose
target: 4.5 to 6.0 mmol/L versus 8.0 to 10.0 mmol/L). A
recently published meta-analysis including this latter
trial showed that IIT significantly increased the risk of
hypoglycemia and conferred no overall mortality benefit
among critically ill patients [14]. The goal of the present
study is to report glucose and mortality data from
cohorts of patients with a medical and a surgical admis-
sion diagnosis from a general ICU of a teaching hospital
in The Netherlands.
Materials and methods
Cohorts, setting, and data collection
We collected information about patients admitted
between January 2004 and December 2007 in a 20-bed
medical/surgical ICU in a teaching hospital (Onze Lieve
Vrouwe Gasthuis [OLVG], Amsterdam, The Nether-
lands) (the OLVG cohort). All data were anonymous
and collected retrospectively, so no ethical approval was
necessary. On average, one nurse took care of two
patients, depending on the severity of disease. All beds
were equipped with a clinical information system (Meta-
Vision; iMDsoft, Tel Aviv, Israel) from which all clinical
and laboratory data were extracted. The glucose regula-
tion algorithm was implemented successfully in 2001
[15], targeting for glucose values of between 4.0 and
7.0 mmol/L. The glucose protocol was started for every
patient at the time of arrival at the ICU. Insulin infusion
was started when admission blood glucose exceeded
7.0 mmol/L. When admission glucose was lower than
7.0 mmol/L, blood glucose was further measured every
2 hours and insulin was started when necessary (that is,
when blood glucose exceeded 7.0 mmol/L). The nursing
staff was instructed to use a dynamic computerized
algorithm to adjust the insulin infusion rate, depending
on the current glucose value and the rate of glucose
change (based on the previous five measurements). The
s o f t w a r ea l s op r o v i d e dt h et i m et h en e x tg l u c o s em e a -
surement was due, which could vary from 15 minutes to
4 hours. Routinely, enteral feeding was started within
24 hours after admission, aiming at 1,500 kcal per
24 hours, and subsequently adjusted to the patient’s
requirements, except for the uncomplicated cardiac sur-
gery patients, who do not receive enteral feeding if extu-
bated within 24 hours. A duodenal feeding tube was
inserted in case of persistent gastric retention. The tight
glucose algorithm was deactivated when patients
resumed normal eating.
We excluded readmissions, patients with a withhold-
ing care policy, and patients with only one glucose value
measured during admission. From the clinical informa-
tion system, we collected demographic variables, mortal-
ity rates in the ICU, and glucose values. For severity of
disease measures, we used the Acute Physiology and
Chronic Health Evaluation II (APACHE II) score [16].
Informed consent was not required according to Dutch
Ethical Review Board regulations, because a retrospec-
tive analysis of anonymous data was performed.
Glucose measures
For each patient, we calculated the mean overall glucose
during admission from all glucose values measured dur-
ing admission and the mean morning glucose from the
first value available between 5 and 7 a.m. per patient
per day. Glucose values mentioned in this paper stand
for mean overall glucose unless stated otherwise. We
calculated the standard deviation (SD) and the mean
absolute glucose (MAG) change [6] per patient as mar-
kers of glycemic variability. Glucose was obtained from
arterial blood samples by means of a handheld glucose
measurement device (AccuChek; Roche/Hitachi, Basel,
Switzerland). Results were automatically stored in the
clinical information system.
Data interpretation
The cohort characteristics are presented as mean ± SD or
as median and interquartile range (IQR), depending on
the distribution of the data. The mean glucose values and
SDs were divided into five strata with equal numbers of
patients per group. For each stratum, the ICU mortality
was calculated. Subsequently, we performed a logistic
regression analysis to calculate the odds ratio (OR) with
95% confidence intervals for ICU mortality per glucose
stratum. The stratum with the lowest mortality incidence
was used as a reference. In this model, we adjusted for
age, sex, severity of disease (APACHE II score), occur-
rence of severe hypoglycemia (≤2.2 mmol/L), and admis-
sion duration (that is, ≤ or >24 hours). The last
adjustment was done because glucose values are higher
and have a wider range in the first 24 hours of admission,
biasing the patients with longer admission times and cor-
responding lower mean glucose values. In a second
model, adjustment for occurrence of mild hypoglycemia
(≤4.7 mmol/L), which is also independently associated
with mortality [17], was made.
Results
In total, 5,828 patients were eligible for analyses of the
mean glucose for the OLVG population after excluding
6 5 6r e a d m i s s i o n s ,8 6p a t i e n t s with a withholding care
policy, and 160 patients with only one glucose value
measured. This cohort consisted of 1,339 patients with a
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and 4,489 patients with a surgical admission diagnosis
(the ‘surgical’ population). In the medical cohort, a med-
ian (IQR) of 34 (15 to 65) glucose values per patient
were collected, and in the surgical cohort, a median
(IQR) of 10 (5 to 14) values were collected. The median
(IQR) admission durations were 64 (30 to 129) hours in
the medical cohort and 22 (18 to 28) hours in the surgi-
cal cohort.
Mean glucose
The overall mean (SD) glucose values of the medical
and surgical populations were 7.9 (2.7) and 8.1 (1.6)
mmol/L, respectively (Table 1). The mean glucose
values of the first 24 hours of admission were higher
and had a wider range than did the mean glucose values
after 24 hours (medical: mean [SD] 8.4 [3.3] mmol/L,
range 3.7 to 40.2 mmol/L and 7.0 [1.4] mmol/L, range
3.2 to 31.1 mmol/L; surgical: mean [SD] 8.3 [1.9] mmol/
L, range 0.6 to 27.5 mmol/L and 7.6 [1.7] mmol/L,
range 3.2 to 15.7 mmol/L). The mean morning glucose
values were 7.4 [2.6] mmol/L in the medical population
and 7.7 [2.3] mmol/L in the surgical population. After
division of the mean glucose of both populations into
five equally sized strata, the lowest mean glucose stra-
tum ranged from 6.7 mmol/L and lower in the medical
cohort and from 7.0 mmol/L and lower in the surgical
cohort. The highest stratum ranged from 8.5 mmol/L
and higher in the medical cohort and from 9.5 mmol/L
and higher in the surgical cohort. Mean glucose ranges
per stratum and corresponding mortality rates per
cohort are displayed in Figure 1. This results in a
U-shaped curve relationship between mean glucose and
m o r t a l i t yi nb o t hc o h o r t s ,w i t hh i g hI C Um o r t a l i t yi n
the lowest and highest glucose strata (medical: 26.9%
and 35.6%; surgical: 3.6% and 1.4%). Logistic regression
analysis showed that in both populations mean glucose
values in the lowest and highest strata were associated
with a significantly higher OR for ICU mortality
compared with the stratum with the lowest mortality
(Figure 2). This results in ‘safe ranges’ of 6.7 to
8.5 mmol/L in the medical cohort and 7.0 to 9.5 mmol/L
in the surgical cohort. The non-linear U-shaped relation-
ship between mean glucose and ICU mortality was
Table 1 Characteristics of the studied cohorts
Medical population Surgical population
Total
n = 1,339
≤6.6 mmol/L
n = 268
’Safe range’
n = 804
≥8.5 mmol/
L
n = 267
Total
n = 4,489
≤6.9
mmol/L
n = 898
’Safe
range’
n = 2,694
≥9.5
mmol/L
n = 897
Age in years, mean ± SD 61.8 ± 16.9 59.0 ± 18.4 62.5 ± 16.2 62.4 ± 17.0 66.0 ± 12.0 66.8 ± 12.5 65.4 ± 12.1 67.2 ± 11.3
Female gender, percentage 38.2 37.3 37.7 40.4 33.2 36.6 32.0 33.4
APACHE II score, mean ± SD 24.6 ± 8.8 24.8 ± 9.1 24.1 ± 8.1 25.8 ± 10.2 15.1 ± 4.6 16.3 ± 5.2 14.8 ± 4.5 14.7 ± 4.2
Diabetes mellitus, percentage 0.6 0.4 0.5 1.1 15.4 23.7 16.4 4.1
Died in the ICU, percentage 20.9 26.9 14.1 35.6 1.6 3.6 1.0 1.4
Died in the hospital, percentage 31.3 35.4 26.6 41.2 4.3 7.5 3.9 2.7
Morning glucose in mmol/L,
mean ± SD
7.4 ± 2.6 5.9 ± 1.0 7.1 ± 1.2 10.3 ± 4.5 7.7 ± 2.3 5.8 ± 1.2 7.3 ± 1.7 10.6 ± 1.9
Overall glucose in mmol/L,
mean ± SD
7.9 ± 2.7 6.0 ± 0.6 7.3 ± 0.5 11.6 ± 4.1 8.1 ± 1.6 6.4 ± 0.5 7.9 ± 0.7 10.7 ± 1.1
Hypoglycemia incidence,
percentage
9.9 18.7 8.8 4.5 1.8 4.8 1.3 0.1
SD, median (IQR) 2.0 (1.5-2.9) 1.6 (1.2-1.9) 2.0 (1.6-2.6) 3.8 (2.7-5.4) 1.8 (1.3-2.3) 1.6 (1.3-2.0) 1.8 (1.4-2.4) 1.9 (1.4-2.6)
MAG change, median (IQR) 0.8 (0.5-1.1) 0.5 (0.3-0.8) 0.8 (0.6-1.0) 1.4 (0.9-2.0) 0.6 (0.4-0.8) 0.5 (0.4-0.7) 0.6 (0.4-0.9) 0.5 (0.3-0.7)
Caloric intake per 24 hours,
mean ± SD
1,103.0 ±
758.4
1,159.3 ±
1,108.6
1,107.1 ±
507.2
1,033.6 ±
944.5
315.0 ±
392.3
427.7 ±
466.6
322.8 ±
387.5
181.5 ±
268.9
Use of insulin, percentage 88.5 79.5 93.3 82.8 64.0 93.1 71.8 11.6
Insulin dose in IU/hour, median
(IQR)
1.4 (0.8-2.4) 0.6 (0.4-1.0) 1.4 (0.9-2.1) 3.4 (2.0-6.2) 1.2 (0.7-1.9) 1.0 (0.7-1.5) 1.3 (0.8-2.0) 1.5 (0.7-3.2)
Use of vasopressor drugs,
percentage
86.0 19.4 11.8 15.4 94.8 94.1 94.2 97.0
Use of corticoids, percentage 92.5 91.0 94.8 86.9 99.1 99.0 99.1 99.1
Mechanical ventilation, percentage 81.6 81.7 85.0 71.2 97.9 97.3 97.9 98.6
CVVH, percentage 16.7 20.1 17.4 11.2 2.6 7.0 1.8 0.8
Characteristics of the studied cohorts are divided by mean glucose ranges. The ‘safe range’ refers to the mean glucose levels associated with the lowest mortality
rates: 6.7 to 8.4 mmol/L in the medical cohort and 7.0 to 9.4 mmol/L in the surgical cohort. Hypoglycemia was defined as at least one glucose value of not more
than 2.2 mmol/L. APACHE II, Acute Physiology and Chronic Health Evaluation II; CVVH, continuous veno-venous hemofiltration; ICU, intensive care unit; IQR,
interquartile range; MAG, mean absolute glucose; SD, standard deviation.
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of the mean glucose levels in this logistic regression
model (P < 0.001). The characteristics of our populations,
also subdivided in groups with low, ‘safe range’,a n dh i g h
glucose values, are displayed in Tables 1 and 2.
Other glycemic measures
Overall, 9.9% and 1.8% of the medical and surgical
patients, respectively, sustained at least one hypoglyce-
mic episode, defined as a glucose value of not more
than 2.2 mmol/L, during ICU admission. Seventeen
point five percent of all deaths during ICU admission
concerned patients who had experienced severe hypogly-
cemia (both groups). Twenty-eight percent of the
patients who were in the lowest mean glucose strata
and who died in the ICU experienced hypoglycemia,
and 72% did not. The incidence of severe and mild
(≤4.7 mmol/L) hypoglycemia in the different mean glu-
cose strata is reported in Figure 3. When we adjusted
the logistic regression model for occurrence of mild
hypoglycemia with a cutoff value of 4.7 mmol/L, which
is also independently associated with mortality [17], the
OR (95% confidence interval) for ICU mortality in
the lowest glucose stratum remained significant (medi-
cal: 2.6 [1.6 to 4.4], P < 0.001; surgical: 4.9 [1.1 to 22.1],
P = 0.04).
In the medical cohort, glucose variability, both when
expressed as the median of individual SDs and MAG
changes [6], linearly increased with increasing glucose
strata (SD median [IQR] 1.6 [1.2 to 1.9] to 3.8 [2.7 to
5.4] mmol/L, P for trend < 0.001; MAG 0.5 [0.3 to 0.8]
to 1.4 [0.9 to 2.0] mmol/L per hour, P for trend 0.007).
However, in the surgical cohort, no consistent trend in
glucose variability across the glucose strata was seen
(SD median [IQR] 1.8 [1.3 to 2.3] mmol/L; MAG 0.6
[0.4 to 0.8] mmol/L per hour). Adjusting the logistic
regression model for variability did not change the
above-described relationship between mean glucose and
mortality (data not shown).
Discussion
The salient finding of this investigation is that in this
mixed medical and surgical cohort of critically ill
patients, mean glucose values of between approximately
7.0 and 9.0 mmol/L during ICU stay were associated
with the lowest OR for ICU mortality, whereas mean
values of below 7.0 and greater than 9.0 mmol/L confer
significantly higher ORs. These results were attained
while using a dynamic glucose a l g o r i t h mt h a tt a r g e t e d
for glucose values of between 4.0 and 7.0 mmol/L. The
finding that hyperglycemia is associated with increased
mortality is in accordance with published literature
[2,18,19]. Also, the U-shaped curve we found, with
increased mortality in the lower and upper parts, is
described earlier in patients with myocardial infarction
during admission [20-22], more generally in patients
with type 2 diabetes mellitus [23], and in the ICU set-
ting [24-26], corroborating this finding. The optimum
glucose levels in the ICU setting reported previously are
s o m e w h a tl o w e rt h a nw ef o u n d .T h i si sp o s s i b l yd u et o
differences in inclusion criteria or uncertainty about the
practice of tight glycemic control [26], lack of regression
analysis between the strata [25], or a different method
to assess mean glucose [24]. Another difference between
Figure 1 Intensive care unit (ICU) mortality (y-axis) per mean glucose stratum (x-axis). (a) Medical population. (b) Surgical population.
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patients admitted after cardiac arrest (Table 2), a popu-
lation with a high mortality rate. Also, the percentage of
patients with diabetes in our cohort might be underesti-
mated since we scored diabetes only when the patient
used anti-hyperglycemic drugs. However, how these fac-
tors might influence the position of the U-curve in rela-
tion to the x-axis is not known.
Hypoglycemia is associated with increased risk of ICU
and hospital mortality [17,27-29]. In our population, the
incidence of hypoglycemia was highest in the lowest
mean glucose cohorts in which mortality was higher as
well. In addition, a significant percentage of the patients
who died had experienced a hypoglycemic episode.
However, hypoglycemia can account only partially for
the high mortality rate in the lowest mean overall
Figure 2 Odds ratio (OR) for mortality (y-axis) per glucose stratum (x-axis) with the highest OR in the lowest and highest strata.
(a) Medical population. (b) Surgical population. Logistic regression model was adjusted for age, sex, APACHE II (Acute Physiology and Chronic
Health Evaluation II) score, admission duration (≤ and >24 hours), and occurrence of severe hypoglycemia. *P < 0.05, **P < 0.001. CI, confidence
interval.
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not experience severe hypoglycemia. Also, when the
logistic regression model was adjusted for occurrence of
severe or mild hypoglycemia, the OR for mortality
remained significantly higher for those patients with a
mean glucose in the lowest quintile. However, it might
be possible that some hypoglycemic episodes were not
recorded because of intermittent sampling, or were
underestimated because of the AccuChek point-of-care
meter used for glucose measurements, the results of
which tend to be higher than those obtained from the
laboratory [30,31]. Therefore, the contribution of hypo-
glycemia to ICU death could be underestimated and
needs further research using continuous glucose mea-
surement. An alternative explanation for increased
mortality at lower glucose values might be that tissues
with insulin-independent glucose uptake may suffer
from insufficient glucose availability at lower concentra-
tions. In our cohort, glucose variability increased with
increasing glucose strata in the medical cohort. In the
surgical cohort, no consistent relationship was found.
Since glucose variability is associated with mortality [6],
it is unlikely that this contributes to the higher mortality
in the lower glucose strata.
In the NICE-SUGAR study, the mean glucose of the
IIT group (6.4 mmol/L) falls into the stratum with
increased mortality compared with the conventional
group (8.0 mmol/L), which lies in the safe range of both
OLVG populations (Figure 1) [13]. Thus, the findings of
the NICE-SUGAR trial are in accordance with the
Table 2 Percentage of patients per APACHE II admission category
Medical population Surgical population
Total
n = 1,339
≤6.6 mmol/L
n = 268
’Safe range’
n = 804
≥8.5 mmol/L
n = 267
Total
n = 4,489
≤6.9 mmol/L
n = 898
’Safe range’
n = 2,694
≥9.5 mmol/L
n = 897
Cardiovascular 18.0 11.6 19.9 18.7 88.2 81.0 88.3 95.1
Sepsis 16.5 22.8 16.0 11.6 1.2 2.8 1.0 0.1
After cardiac arrest 21.6 11.9 21.5 31.5 0.2 0.6 0.1 0.1
Gastrointestinal 4.3 4.1 4.2 4.9 5.3 8.7 5.0 2.8
Hematological 0.6 0.7 0.7 0 0.2 0.4 0.1 0.1
Renal 1.9 1.5 1.0 5.2 0.3 0.6 0.2 0.1
Metabolic 3.6 3.0 2.7 6.7 0.2 0.1 0.2 0.1
Neurological 11.5 18.3 10.3 8.2 0.9 1.1 1.0 0.3
Respiratory 22.0 26.1 23.5 13.1 3.6 4.8 4.0 1.2
The ‘safe range’ refers to the mean glucose levels associated with the lowest mortality rates: 6.7 to 8.4 mmol/L in the medical cohort and 7.0 to 9.4 mmol/L in
the surgical cohort. APACHE II, Acute Physiology and Chronic Health Evaluation II.
Figure 3 Hypoglycemia incidence (y-axis) per mean glucose stratum (x-axis). (a) Medical population. (b) Surgical population. The y-axis
represents the percentage of patients experiencing at least one severe (≤2.2 mmol/L, left bars) and mild (≤4.7 mmol/L, right bars) hypoglycemic
event.
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the data of both Leuven studies. The means of the IIT
groups of both the Leuven studies (6.1 mmol/L in the
medical population [8] and 5.7 mmol/L in the surgical
population [7]) fall into the lowest mean glucose stra-
tum in the corresponding OLVG cohorts, in which mor-
tality is highest. The means of the conventional groups
in the Leuven studies (8.5 mmol/L in the medical as
well as in the surgical population [7,8]) lie in the safe
ranges of both OLVG populations (Figure 1).
A possible explanation for the low mortality of the
Leuven IIT group might be the way of feeding. In a
recent paper, Marik and Preiser [32] suggested that the
use of intravenous calories could explain differences
between populations treated with IIT, with a positive
effect of IIT in patients who receive most of their cal-
ories intravenously. In our population, as opposed to
the Leuven studies, only 0.7% of carbohydrates were
given parenterally. In populations predominantly fed
parenterally, the relationship between mean overall
glucose and mortality might be different. Also, glyce-
m i cs w i n g sa r eak n o w nr i s kf a c t o ro fI C Ud e a t ha n d
might contribute to differences in mortality rate [4,5].
However, it is unlikely that differences in glucose
variability explain the higher mortality in our cohort
compared with the Leuven IIT group as the medians
(IQR) of the individual median SDs are roughly com-
parable (Leuven medical 1.99 [1.57 to 2.66] mmol/L
[33] and OLVG medical 2.03 [1.54 to 2.86] mmol/L).
In addition, other explanations have been proposed to
explain the diverging outcomes of Leuven and NICE-
SUGAR [34].
The mean glucose of the OLVG population (medical:
7.9 mmol/L; surgical: 8.1 mmol/L) was higher than the
target range, which was between 4.0 and 7.0 mmol/L.
Other studies of IIT also did not reach their target
range, illustrating the difficult implementation of this
therapy [10,12,13]. The high percentage of corticoster-
oid treatment in our population might have contribu-
ted (Table 1). Also, the relatively short ICU duration
of stay in the predominantly surgical population of the
OLVG explains that mean glucose is slightly higher
than the target (median ICU stay was 22 hours in our
cohort compared with 3 days in the Leuven cohort
and 4.2 days ‘on algorithm’ in the NICE-SUGAR
study) because of the time needed to reach target. Glu-
cose values were indeed higher and had a wider range
in the first 24 hours of admission. Furthermore, our
patients were treated in a normal-care setting without
the extra stimuli of a trial setting to achieve the target.
It should be noted that mean glucose does not equal
time in target range, since the protocol requires more
frequent sampling when not in target, thus falsely
inflating the mean.
In our logistic regression model, we adjusted for
severity of disease and admission duration less or more
than 24 hours since both high and low glucose levels
could be a manifestation, rather than a cause, of severe
disease. Glucose values are higher and have a wider
range in the first 24 hours of admission, biasing the
patients with longer admission times and correspond-
ing lower mean glucose values. A limitation of our cor-
rection for severity of disease is the use of the
APACHE II score, because the use of APACHE II
score to predict mortality is not validated for cardiac
surgery patients. However, this adjustment is the best
available method [35].
Conclusions
In our mixed cohort of surgical and medical patients,
the mean glucose during ICU stay was related to mor-
tality by a U-shaped curve; a ‘safe range’ for mean glu-
cose can be defined as between approximately 7.0 and
9.0 mmol/L, while both higher and lower mean values
are associated with higher mortality. This finding
applied to the surgical as well as the medical patients.
Hypoglycemia seems to only partially explain the high
mortality rate in the lowest mean glucose quintile, and
glucose variability does not. Second, comparison of the
combined Leuven, NICE-SUGAR, and our cohorts
demonstrates that the increased mortality in the IIT
group of NICE-SUGAR is in line with our U-shaped
curve but that the low mortality in the intensively trea-
ted Leuven group is not. The percentage of calories
given parenterally may influence the relationship
between mean glucose and mortality. We await further
studies, but according to these findings, we recommend
treating hyperglycemia in the ICU in a moderately
intensive way in both medical and surgical patients, tar-
geting for mean glucose values of between approxi-
mately 7.0 and 9.0 mmol/L and avoiding hypoglycemia.
This ‘safe range’ should be studied prospectively in ran-
domized clinical trials.
Key messages
￿ During ICU admission, mean glucose relates to
mortality by a U-shaped curve.
￿ A mean glucose range of 7.0 to 9.0 mmol/L is
associated with the lowest mortality in our cohort.
￿ Occurrence of hypoglycemia does not fully explain
the high mortality in the lower glucose strata.
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